Module

EGFR-Targeted Antibodies: Clinical Applications, Treatment Challenges, and Ongoing Scientific Research

Source: Translating Science Into Clinical Practice: Recent Lessons in EGFR Inhibition, Multitargeted TKIs, and the Tumor Microenvironment

EGFR-Targeted Antibodies: Clinical Applications, Treatment Challenges, and Ongoing Scientific Research


Program Director: Ezra E. W. Cohen, MD, FRCPC

Faculty:

David Cunningham, MD, FRCP
  • David Cunningham, MD, FRCP

CME CREDIT INFORMATION

Release Date: 08/13/08

Expiration Date: 08/12/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status

Begin the Module

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Recall anti-EGFR monoclonal antibodies used to treat gastrointestinal malignancies
  • Describe the evaluation of KRAS as a biomarker for efficacy in the setting of colorectal cancer
  • Discuss results of recent clinical trials combining anti-EGFR antibodies with chemotherapy for the treatment of gastrointestinal malignancies
  • Explain the significance of anti-EGFR antibody–associated acneiform rash

Topics covered include:

  • Introduction to EGFR-Targeted Antibodies
  • Cetuximab in Previously Treated Colorectal Cancer
  • Cetuximab in Newly Diagnosed mCRC: The CRYSTAL Study
  • EGFR Inhibitor–Associated Rash
  • Panitumumab as Second-Line Treatment
  • Prognostic Indicators in mCRC
  • Clinical Studies of Targeted Therapies in Upper Gastrointestinal Tract Cancers
  • Dual Targeting of EGFR and VEGF in mCRC
  • Future Directions
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.